Home Medizin Ein Forscher sagt, dass sich die Grippeimpfstoffe in den USA voraussichtlich von vierwertig auf dreiwertig verlagern werden

Ein Forscher sagt, dass sich die Grippeimpfstoffe in den USA voraussichtlich von vierwertig auf dreiwertig verlagern werden

von NFI Redaktion

Currently, all influenza vaccines in the United States are quadrivalent, meaning they protect against four different flu viruses.

In a new article published in the New England Journal of Medicine, researchers detail the spread of the Influenza B/Yamagata virus, which has not been circulating since early 2020; the regulatory discussions and recommendations for updating vaccines; and considerations for manufacturing new vaccine formulations for the US and abroad.

„The removal of the B/Yamagata virus is logical, as we do not want to include a virus in the vaccine formulation that is no longer circulating.“

Arnold Monto, Emeritus Professor of Epidemiology and Global Public Health, UM School of Public Health

„It also gives us the opportunity to replace the B/Yamagata virus with a component that provides better protection against the circulating influenza viruses. Additional studies are needed to achieve this.“

Monto has dedicated his career to researching the occurrence, prevention, and control of respiratory infections. He is also a member of the Vaccines and Related Biological Products Advisory Committee of the US Food and Drug Administration.

Co-authors include Maria Zambon from the UK Health Security Agency and Jerry Weir from the Division of Viral Products, Center for Biologics Evaluation and Research at the US Food and Drug Administration.

Source:

Journal Reference:

Monto, AS, et al. (2024) The End of B/Yamagata Influenza Transmission – Transition to Quadrivalent Vaccines. New England Journal of Medicine. doi.org/10.1056/NEJMp2314801.

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.